Thomas Dyrberg M.D., Ph.D.
Thomas Dyrberg, M.D., Ph.D. serves as a Senior Partner of Novo Ventures and Novo A/S. He previously held research positions at the Hagedorn Research Institute in Gentofte, Denmark and at the Scripps Research Institute in La Jolla, Calif., and has published several articles within the fields of diabetes, immunology and autoimmunity. Dr. Dyrberg has also worked for Novo Nordisk A/S in health care discovery and clinical drug development as an International Clinical Project Manager.
He currently serves or has served on the board of directors of several biotechnology companies, including Veloxis Pharmaceuticals A/S, Gloucester Pharmaceuticals, Inc., Rejuvenon Corp., Allocure Inc., Veloxis, Lux Biosciences, Inc., Sapphire Therapeutics Inc., Delenex Therapeutics AG, BioMimetic Therapeutics, Inc. and Helsinn Therapeutics (U.S.), Inc.
Dr. Dyrberg received his M.D. degree from the University of Copenhagen in 1981 and his Doctor of Medical Science (D.M.Sc.) degree, also from the University of Copenhagen, in 1986.